Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

Pulmonary hypertension is a progressive disease of various origins that is associated with vascular remodelling and results in right heart dysfunction. Accumulating evidence indicates important roles of immune cells and inflammatory chemokines in the pathogenesis and progression of pulmonary hypertension. We have identified CCL21 as anti-remodelling efficacy biomarker for pulmonary hypertension. CCL21 was found to be highly sensitive and specific in discriminating pulmonary hypertension patients from matched controls. CCL21 was upregulated in pulmonary hypertension and down-regulated with treatment with an anti-remodelling agent.

The invention relates to stabilized Adrenomedullin derivatives and use thereof. In particular, the invention relates to novel, biologically active, stabilized Adrenomedullin (ADM) compounds. The invention further relates to the compounds for use in a method for the treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders, and to medicaments comprising the compounds for treatment and/or prevention of cardiovascular, edematous and/or inflammatory disorders.

The invention relates to stabilized Adrenomedullin derivatives and use thereof. In particular, the invention relates to novel, biologically active, stabilized Adrenomedullin (ADM) compounds. The invention further relates to the compounds for use in a method for the treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders, and to medicaments comprising the compounds for treatment and/or prevention of cardiovascular, edematous and/or inflammatory disorders.

A drug containing, as an active ingredient, a compound having an antagonistic activity against an EP.sub.2 receptor in the prevention and/or treatment of a disease associated with the activation of an EP.sub.2 receptor, of formula (I-A):

##STR00001##

wherein all symbols have the same meanings as those described in the specification, or a pharmaceutically acceptable salt thereof.

Disclosed herein are compositions and methods for treating pulmonary hypertension whereby a SCUBE1 polynucleotide or polypeptide is administered. Also disclosed herein are methods for diagnosing and/or prognosing pulmonary arterial hypertension or pulmonary hypertension with high pulmonary vascular resistance that include detecting an amount of a SCUBE1 polynucleotide or polypeptide.

Disclosed herein are compositions and methods for treating pulmonary hypertension whereby a SCUBE1 polynucleotide or polypeptide is administered. Also disclosed herein are methods for diagnosing and/or prognosing pulmonary arterial hypertension or pulmonary hypertension with high pulmonary vascular resistance that include detecting an amount of a SCUBE1 polynucleotide or polypeptide.

A crystalline form A of a nitrogen-containing tricyclic compound shown in formula (I), a pharmaceutical composition containing the crystalline form A, and the use of the crystalline form A or the pharmaceutical composition in the preparation of a medication for preventing, treating or relieving an FXR-mediated disease of a patient.

Provided are a compound for modulating the activity of FXR having a structure of formula (I), a pharmaceutically acceptable salt, an ester or a stereoisomer thereof.

##STR00001##

New medical uses for the compounds of Formula I, II, or III or a pharmaceutically acceptable salt thereof.